{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"5.32","value":"2.7"},{"groupId":"OG001","lowerLimit":"2.56","upperLimit":"4.76","value":"2.7"},{"groupId":"OG002","lowerLimit":"2.60","upperLimit":"16.82","value":"16.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"PFS is defined as the time from first study drug administration to the date of disease progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"},{"description":"Participants with R/R cutaneous T-cell lymphoma \\[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG002","title":"Cohort 3: MF and SS"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 1 week","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}